Beijing Luzhu Biotechnology Co., Ltd. Class H

As of June 30, 2026, Beijing Luzhu Biotechnology Co., Ltd. Class H carries a market capitalization of 2.55B, placing it among publicly traded companies globally. Its enterprise value stands at 2.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beijing Luzhu Biotechnology Co., Ltd. Class H's next confirmed earnings release is scheduled for March 24, 2027.

As of June 30, 2026, Beijing Luzhu Biotechnology Co., Ltd. Class H has 198.91M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Beijing Luzhu Biotechnology Co., Ltd. Class H maintains a current ratio of 3.18, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Beijing Luzhu Biotechnology Co., Ltd. Class H's stock has declined approximately 34.25% over the past 52 weeks. The 50-day moving average sits at 13.91, while the 200-day moving average is 18.58.

As of June 30, 2026, Beijing Luzhu Biotechnology Co., Ltd. Class H holds 424.86M in cash and equivalents against 362.41M in total debt, resulting in a net debt position of 200.04M. Total book value stands at 691.73M, with working capital of 310.79M providing operational flexibility.